Upgrade to SI Premium - Free Trial

Best Smidcap Ideas: TD Cowen Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)

June 17, 2026 9:19 AM
TD Cowen analyst Phil Nadeau reiterated a Buy rating and $130.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments